Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Finished Goods (2017 - 2025)

Dexcom (DXCM) has disclosed Finished Goods for 12 consecutive years, with $266.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Finished Goods rose 42.21% to $266.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $266.5 million, a 42.21% increase, with the full-year FY2025 number at $266.5 million, up 42.21% from a year prior.
  • Finished Goods was $266.5 million for Q4 2025 at Dexcom, up from $259.5 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $266.5 million in Q4 2025 to a low of $107.9 million in Q1 2025.
  • A 5-year average of $187.5 million and a median of $190.5 million in 2023 define the central range for Finished Goods.
  • Peak YoY movement for Finished Goods: surged 209.87% in 2021, then tumbled 54.68% in 2025.
  • Dexcom's Finished Goods stood at $195.9 million in 2021, then crashed by 33.38% to $130.5 million in 2022, then skyrocketed by 61.0% to $210.1 million in 2023, then decreased by 10.8% to $187.4 million in 2024, then skyrocketed by 42.21% to $266.5 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Finished Goods are $266.5 million (Q4 2025), $259.5 million (Q3 2025), and $130.6 million (Q2 2025).